%20-%20http://www.bohemiancoding.com/sketch%20--%3e%3ctitle%3eIcon/Menu%3c/title%3e%3cdesc%3eCreated%20with%20Sketch.%3c/desc%3e%3cdefs%3e%3cpolygon%20id='path-1'%20points='0.0005%200.646%2022.386%200.646%2022.386%203.1455%200.0005%203.1455'%3e%3c/polygon%3e%3cpolygon%20id='path-3'%20points='0.0005%200.9341%2022.386%200.9341%2022.386%203.4341%200.0005%203.4341'%3e%3c/polygon%3e%3cpolygon%20id='path-5'%20points='0.0005%200.5%2022.386%200.5%2022.386%203%200.0005%203'%3e%3c/polygon%3e%3c/defs%3e%3cg%20id='Symbols'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%3e%3cg%20id='Icon/Menu'%3e%3cg%20id='Group-10-Copy'%20transform='translate(3.800000,%205.300000)'%3e%3cg%20id='Group-3'%20transform='translate(0.000000,%200.354500)'%3e%3cmask%20id='mask-2'%20fill='white'%3e%3cuse%20xlink:href='%23path-1'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-2'%3e%3c/g%3e%3cpath%20d='M22.3865,2.6455%20C22.3865,2.9205%2022.1615,3.1455%2021.8865,3.1455%20L0.5005,3.1455%20C0.2245,3.1455%200.0005,2.9205%200.0005,2.6455%20L0.0005,1.1455%20C0.0005,0.8705%200.2245,0.6455%200.5005,0.6455%20L21.8865,0.6455%20C22.1615,0.6455%2022.3865,0.8705%2022.3865,1.1455%20L22.3865,2.6455%20Z'%20id='Fill-1'%20fill='%23FFFFFF'%20mask='url(%23mask-2)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-6'%20transform='translate(0.000000,%207.354500)'%3e%3cmask%20id='mask-4'%20fill='white'%3e%3cuse%20xlink:href='%23path-3'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-5'%3e%3c/g%3e%3cpath%20d='M22.3865,2.9341%20C22.3865,3.2091%2022.1615,3.4341%2021.8865,3.4341%20L0.5005,3.4341%20C0.2245,3.4341%200.0005,3.2091%200.0005,2.9341%20L0.0005,1.4341%20C0.0005,1.1591%200.2245,0.9341%200.5005,0.9341%20L21.8865,0.9341%20C22.1615,0.9341%2022.3865,1.1591%2022.3865,1.4341%20L22.3865,2.9341%20Z'%20id='Fill-4'%20fill='%23FFFFFF'%20mask='url(%23mask-4)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-9'%20transform='translate(0.000000,%2015.354500)'%3e%3cmask%20id='mask-6'%20fill='white'%3e%3cuse%20xlink:href='%23path-5'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-8'%3e%3c/g%3e%3cpath%20d='M22.3865,2.5%20C22.3865,2.775%2022.1615,3%2021.8865,3%20L0.5005,3%20C0.2245,3%200.0005,2.775%200.0005,2.5%20L0.0005,1%20C0.0005,0.725%200.2245,0.5%200.5005,0.5%20L21.8865,0.5%20C22.1615,0.5%2022.3865,0.725%2022.3865,1%20L22.3865,2.5%20Z'%20id='Fill-7'%20fill='%23FFFFFF'%20mask='url(%23mask-6)'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23fff'%20fill-rule='nonzero'%3e%3cg%20id='icon/fold'%20transform='translate(240.000000,%20272.000000)'%3e%3cpath%20d='M11.5,2.3%20C6.4216,2.3%202.3,6.4216%202.3,11.5%20C2.3,16.5784%206.4216,20.7%2011.5,20.7%20C16.5784,20.7%2020.7,16.5784%2020.7,11.5%20C20.7,6.4216%2016.5784,2.3%2011.5,2.3%20Z%20M10.58,18.7956%20C6.946,18.3448%204.14,15.2536%204.14,11.5%20C4.14,10.9296%204.2136,10.3868%204.3332,9.8532%20L8.74,14.26%20L8.74,15.18%20C8.74,16.192%209.568,17.02%2010.58,17.02%20L10.58,18.7956%20Z%20M16.928,16.4588%20C16.6888,15.7136%2016.008,15.18%2015.18,15.18%20L14.26,15.18%20L14.26,12.42%20C14.26,11.914%2013.846,11.5%2013.34,11.5%20L7.82,11.5%20L7.82,9.66%20L9.66,9.66%20C10.166,9.66%2010.58,9.246%2010.58,8.74%20L10.58,6.9%20L12.42,6.9%20C13.432,6.9%2014.26,6.072%2014.26,5.06%20L14.26,4.6828%20C16.9556,5.7776%2018.86,8.418%2018.86,11.5%20C18.86,13.4136%2018.124,15.1524%2016.928,16.4588%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates
2015/05/07
合全药业“新三板”挂牌仪式在京举行
2015年5月7日，上海合全药业股份有限公司（股票简称：合全药业；股票代码：832159）“新三板”上市挂牌仪式在北京金融街全国中小企业股份转让系统公司挂牌大厅隆重举行。药明康德董事长兼首席执行官、合全药业董事长李革博士，合全药业首席执行官陈民章博士等药明康德及合全药业的公司管理层人员，来自中介机构中金公司、华兴资本、德勤和嘉源所的代表以及上海金山、江苏常州等地方政府领导敲响合全药业的开市宝钟，共同见证这一重要发展里程碑。
阅读更多2015/04/08
2001年诺贝尔化学奖得主Barry Sharpless教授访问药明康德
4月8日，世界知名化学家、2001年诺贝尔化学奖获得者巴里·夏普莱斯（Barry Sharpless）教授访问药明康德上海总部，并为药明康德相关科研人员做了精彩的学术讲座。药明康德于2007年开设“药明康德学术研讨会”年度讲座项目，定期邀请行业知名专家、学者到公司进行学术交流，举办学术讲座，以此培养和鼓励药明康德的青年科学家们在科研工作中勇攀高峰，不断追求卓越。
阅读更多2015/02/09
康德保瑞宣布两项重要人事任命
康德保瑞近日宣布两项重要人事任命：徐列东先生出任康德保瑞执行副总裁兼首席运营官，吴济生先生担任公司执行副总裁兼首席医务官。徐列东先生在医药及医疗器械领域拥有22年丰富行业经验，曾先后在默沙东艾尔建、雅培参天和默克雪兰诺担任管理职务。吴济生先生从业20余年，先后在恩微生活、Auxillium、赛诺菲以及辉瑞等公司从事临床研究以及产品开发等方面的管理工作。
阅读更多2015/02/02
药明康德子公司合全药业获评“CMO领军企业奖”
药明康德宣布其子公司合全药业荣获行业权威杂志Life Science Leader颁发的2015 “CMO领军企业奖”。该奖项基于Life Science Leader杂志对全球超过2300位生物医药行业企业高管的意见调查，从质量、产能、可靠性等多个方面对CMO（药物研发生产企业）进行客观评选。合全药业作为药明康德小分子药物生产基地，凭借其在广大行业客户中的良好口碑，被评为“CMO领军企业-最可信赖奖”。此前合全药业还曾于2012年获评“CMO领军企业—最佳质量奖”。
阅读更多2015/01/05
药明康德推出“掌上化学”移动应用APP
药明康德今日宣布推出全球首款针对小分子化学定制合成服务的移动应用APP“掌上化学”（WuXi V-Lab）。通过该款应用，全球研发人员可以在手机等移动客户端更加方便快捷地订购各种有机小分子化合物，并可在线完成询价、报价、订单确认、项目进度查询、交付确认、支付等功能，实现线上与线下的实时交流。“掌上化学”移动应用APP下载链接地址为http://www.wuxiapptec.com/WXVLab。
阅读更多